W
Wendy Verret
Researcher at Genentech
Publications - 39
Citations - 4563
Wendy Verret is an academic researcher from Genentech. The author has contributed to research in topics: Atezolizumab & Bevacizumab. The author has an hindex of 11, co-authored 27 publications receiving 1767 citations.
Papers
More filters
Journal ArticleDOI
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn,Shukui Qin,Masafumi Ikeda,Peter R. Galle,Michel Ducreux,Tae-You Kim,Masatoshi Kudo,Valeriy Breder,Philippe Merle,Ahmed O Kaseb,Daneng Li,Wendy Verret,Derek-Zhen Xu,Sairy Hernandez,Juan Liu,Chen Huang,Sohail M. Mulla,Yulei Wang,Ho Yeong Lim,Andrew X. Zhu,Ann-Lii Cheng,IMbrave Investigators +21 more
TL;DR: In patients with unresectable hepatocellular carcinoma, atezolIZumab combined with bevacizumab resulted in better overall and progression-free survival outcomes than sorafenib.
Journal ArticleDOI
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
Michael S. Lee,Baek Yeol Ryoo,Chih-Hung Hsu,Kazushi Numata,Stacey Stein,Wendy Verret,Stephen P. Hack,Jessica Spahn,Bo Liu,Heba Abdullah,Yulei Wang,Aiwu Ruth He,Kyung Hun Lee,Y-J. Bang,Johanna C. Bendell,Yee Chao,Jen-Shi Chen,Ho-Sun Chung,Samantha Davis,A. Dev,Edward Gane,Benson M. George,Aiwu R. He,H. Hochster,Chiun Hsu,Masanori Ikeda,J.W. Lee,Myung-Mook Lee,Amit Mahipal,Gulam Abbas Manji,Manabu Morimoto,K. Numata,Michael J. Pishvaian,Shukui Qin,David P. Ryan,Baek-Yeol Ryoo,N. Sasahira,S. Stein,John H. Strickler,Niall C. Tebbutt +39 more
TL;DR: Primary endpoints were confirmed objective response rate in all patients who received the combination treatment for group A and progression-free survival in the intention-to-treat population in group F, both assessed by an independent review facility according to Response Evaluation Criteria in Solid Tumors version 1.1.
Journal ArticleDOI
IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).
Richard S. Finn,Shukui Qin,Masafumi Ikeda,Peter R. Galle,Michel Ducreux,Tae-You Kim,Ho Yeong Lim,Masatoshi Kudo,Valeriy Breder,Philippe Merle,Ahmed Kaseb,Daneng Li,Wendy Verret,Hui Shao,Juan Liu,Lindong Li,Andrew X. Zhu,Ann-Lii Cheng +17 more
TL;DR: Atezo + bev has been approved globally for pts with unresectable HCC who have not received prior systemic therapy, based on results from IMbrave150 (NCT03434379).
Journal ArticleDOI
IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)
A-L Cheng,S. Qin,Masafumi Ikeda,Peter R. Galle,Michel Ducreux,Andrew X. Zhu,Tae Yong Kim,Masatoshi Kudo,V. Breder,Philippe Merle,Ahmed Kaseb,Daneng Li,Wendy Verret,Z.-X. Xu,Sairy Hernandez,Juan Liu,Chen Huang,S. Mulla,H.Y. Lim,Richard S. Finn +19 more
Journal ArticleDOI
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
Peter R. Galle,Richard S. Finn,Shukui Qin,Masafumi Ikeda,Andrew X. Zhu,Tae-You Kim,Masatoshi Kudo,Valeriy Breder,Philippe Merle,Ahmed Kaseb,Daneng Li,S. Mulla,Wendy Verret,Derek Zhen Xu,Sairy Hernandez,Beiying Ding,Juan Liu,Chen Huang,Ho Yeong Lim,Ann-Lii Cheng,Michel Ducreux +20 more
TL;DR: The IMbrave150 trial as mentioned in this paper evaluated patient-reported outcomes (PROs) with atezolizumab plus bevacizumaab versus sorafenib in patients with advanced hepatocellular carcinoma.